TransCode Therapeutics (RNAZ) Registration filing summary

Company overview and business model

• Clinical-stage company focused on immuno-oncology and RNA therapeutics for high-risk and advanced cancers, with a diversified pipeline including two clinical-stage assets and multiple preclinical programs.

• Lead programs include TTX-MC138 (antisense inhibitor of oncogenic microRNA) and Seviprotimut-L (cancer vaccine), both with orphan drug designations for certain indications.

• Proprietary TTX drug design engine enables modular, tumor-targeted RNA delivery, aiming to address previously undruggable cancer targets.

• Recent acquisitions and licensing agreements have expanded the pipeline to include oncolytic immunotherapy candidates and additional RNA-based therapeutics.

Financial performance and metrics

• As of April 29, 2026, 916,968 shares of common stock were outstanding.

• Received $950,000 in gross proceeds from the sale of a convertible note and may receive up to $4.75 million from a second note and up to $14 million from equity sales under the SEPA.

• Auditors have included a going concern explanatory paragraph in the most recent financial statements.

Use of proceeds and capital allocation

• Proceeds from the SEPA and convertible notes are expected to be used for general corporate purposes, including working capital.

• Management retains broad discretion over the use of funds raised.